M Holdings Securities Inc. Buys 45,082 Shares of Bristol Myers Squibb Company $BMY

Key Points

• M Holdings Securities opened a new position in Bristol Myers Squibb, buying 45,082 shares worth approximately $2.84 million in the third quarter. Institutional investors collectively own 76.41% of the stock.
• Bristol Myers Squibb reported quarterly EPS of $1.35, beating the $1.10 consensus estimate, and revenue of $13.07 billion, up 6.9% year over year. The company also pays a quarterly dividend of $0.63, equivalent to a 4.1% yield at the cited share price.
• Analysts’ consensus rating is Hold, with an average price target of $65.46; the stock was recently quoted at $62.20.

M Holdings Securities Inc. purchased a new position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 45,082 shares of the biopharmaceutical company's stock, valued at approximately $2,839,000.

A number of other institutional investors also recently bought and sold shares of BMY. Lazard Asset Management LLC lifted its position in shares of Bristol Myers Squibb by 23.7% during the 1st quarter. Lazard Asset Management LLC now owns 1,924,036 shares of the biopharmaceutical company's stock worth $116,693,000 after buying an additional 368,193 shares during the last quarter. Callan Family Office LLC purchased a new position in shares of Bristol Myers Squibb in the 2nd quarter valued at $3,575,000. Saudi Central Bank grew its position in shares of Bristol Myers Squibb by 90.2% in the 2nd quarter. Saudi Central Bank now owns 142,922 shares of the biopharmaceutical company's stock valued at $8,235,000 after buying an additional 67,780 shares during the last quarter. BlackRock Inc. raised its stake in Bristol Myers Squibb by 5.1% during the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company's stock worth $10,393,783,000 after acquiring an additional 8,702,106 shares in the last quarter. Finally, Envestnet Asset Management Inc. raised its stake in Bristol Myers Squibb by 17.4% during the 2nd quarter. Envestnet Asset Management Inc. now owns 2,142,754 shares of the biopharmaceutical company's stock worth $123,465,000 after acquiring an additional 317,360 shares in the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol Myers Squibb Price Performance

Bristol Myers Squibb stock opened at $62.20 on Monday. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.59 and a quick ratio of 1.44. The business has a 50 day simple moving average of $62.34 and a 200-day simple moving average of $60.11. Bristol Myers Squibb Company has a 12 month low of $45.26 and a 12 month high of $68.64. The stock has a market capitalization of $127.15 billion, a PE ratio of 13.79, a price-to-earnings-growth ratio of 0.32 and a beta of 0.20.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.10 by $0.25. The company had revenue of $13.07 billion for the quarter, compared to analysts' expectations of $12.72 billion. Bristol Myers Squibb had a net margin of 18.47% and a return on equity of 60.48%. Bristol Myers Squibb's revenue was up 6.9% compared to the same quarter last year. During the same period in the previous year, the company posted $1.63 EPS. Equities analysts predict that Bristol Myers Squibb Company will post 6.45 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd were issued a $0.63 dividend. The ex-dividend date of this dividend was Friday, October 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.1%. Bristol Myers Squibb's payout ratio is presently 55.88%.

Insider Activity

In other news, SVP Phil M. Holzer sold 500 shares of the business's stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the transaction, the senior vice president directly owned 16,862 shares in the company, valued at $1,138,185. The trade was a 2.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Julia A. Haller sold 3,800 shares of the business's stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $63.31, for a total transaction of $240,578.00. Following the transaction, the director owned 30,279 shares in the company, valued at approximately $1,916,963.49. This trade represents a 11.15% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.05% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

BMY has been the subject of several research analyst reports. TD Cowen initiated coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a "buy" rating for the company. Truist Financial set a $70.00 target price on Bristol Myers Squibb in a research report on Friday, October 30th. BMO Capital Markets reissued a "market perform" rating on shares of Bristol Myers Squibb in a report on Monday, July 27th. Piper Sandler reduced their target price on Bristol Myers Squibb from $82.00 to $78.00 and set an "overweight" rating for the company in a report on Monday, October 26th. Finally, Citigroup reissued a "neutral" rating and issued a $70.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, August 3rd. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $65.46.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb reported 56-week Phase 3 results for Camzyos (mavacamten) in children with symptomatic obstructive hypertrophic cardiomyopathy. Sustained efficacy could support the drug’s potential in a broader patient population, though the report does not say that pediatric use has been approved. Article: Bristol-Myers Squibb Says Camzyos Shows Sustained Efficacy in Phase 3 Pediatric Trial
• Positive Sentiment: A multi-year AI alliance expands the company’s neuroscience efforts, potentially supporting future drug discovery, although the supplied report gives no financial terms or near-term revenue outlook. Article: Bristol Myers Squibb Expands Neuroscience Push With Multi Year AI Alliance
• Positive Sentiment: Recent coverage also highlighted FDA accelerated approval for ZENBEXUS in multiple myeloma and positive trial updates in other diseases. These developments add to the pipeline narrative, though investors may weigh how much expected optimism is already reflected in the shares. Article: Bristol Myers Squibb Wins FDA Approval
• Neutral Sentiment: A company director disclosed selling 3,800 shares. Insider sales can attract attention, but the filing alone does not establish the director’s reason or signal a change in the company’s outlook. SEC Form 4 filing
• Negative Sentiment: A dividend-focused article flags potential pressure from an expected $1.5 billion–$2 billion decline in blood-thinner sales and the company’s debt burden. That raises questions about dividend sustainability, though the article does not establish that a cut is imminent. Article: Bristol Myers Squibb Yields Over 4%. Can Its Dividend Survive 2027?

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease.

The company's medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.

Bristol Myers Squibb was formed in 1989 through the merger of Bristol-Myers, founded in 1887, and the E.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.